# Hisamitsu Pharmaceutical Co., Inc. Q2 FY02/2015 Results

This presentation material contains information that constitutes forwardlooking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

# Hisamitsu Pharmaceutical Co., Inc. Oct. 9<sup>th</sup>, 2014

**Care of People Around the World with Patch** 

disamitsu

# Agenda

- 1. Looking back on the Q2 FY02/2015
- 2. Consolidated PL
- **3.** Non-consolidated PL
- 4. Noven PL
- 5. Sales results by product
- 6. Trends of second-generation non-steroidal anti-inflammatory patch in Japan
- 7. R&D Pipeline

# 1. Looking back on the Q2 FY02/2015

Japan / Developed products	Approval of the additional indication for chronic pain of the Fentos® Tape (development code:HFT-290) in Japan.
Japan / OTC products	Launch of Feitas® Z DICSAS®, Feitas® Z DICSAS®(large size), Feitas® Z cream and Feitas® Zα lotion in Japan.







Feitas® Z DICSAS®

Feitas® Z DICSAS®(large size)

Feitas® Z cream

Feitas® Za lotion

Care of People Around the World with Patch

### Alsamitsu

disamitsu

## 2. Consolidated PL (1) - Performance comparison with the previous period -

			Un	it:¥ million
	Actual performance for FY02/14 (Q1-Q2) (Q1-Q2)		Change	Percentage change
Net sales	77,382	77,052	-330	-0.4%
CoGS	28,018	27,901	-117	-0.4%
as a % of sales	36.2%	36.2%	_	
SG&A costs	36,900	38,795	+1,895	+5.1%
Sales promotion costs	7,098	9,248	+2,150	+30.3%
Advertising costs	6,638	5,800	-838	-12.6%
R&D spending	6,570	6,732	+162	+2.5%
Others	16,594	17,015	+421	+2.5%
Operating profits	12,462	10,355	-2,107	-16.9%
Recurring profits	16,856	15,572	-1,284	-7.6%
Net profits	13,681	9,574	-4,107	-30.0%

### disamitsu

## 2. Consolidated PL (2) - Summary of Profit and Loss -


				Unit.¥ million
	Actual performance for FY02/14 (Q1-Q2)	Actual performance for FY02/15 (Q1-Q2)	Change	Main factors
Net sales	77,382	77,052	-330	
Hisamitsu (Non-consolidated)	64,293	61,113	,	•Decrease in sales of Rx Business.
Noven	8,388	10,160	+1,772	<ul> <li>Increase in sales of major products.</li> <li>Influence of currency exchange rate.</li> </ul>
Others *	4,701	5,779	+1,078	<ul> <li>Increase in sales of overseas subsidiaries.</li> </ul>
CoGS	28,018	27,901	-117	•Decrease in Net sales.
as a % of sales	36.2%	36.2%	-	•Change of sales mix.
SG&A costs	36,900	38,795	+1,895	<ul> <li>Increase in SG&amp;A costs of Noven.</li> <li>Influence of currency exchange rate.</li> </ul>
Operating profits	12,462	10,355	-2,107	
Non-operating balance	4,393	5,217	+824	<ul> <li>Equity-method investment profits of Noven.</li> <li>Influence of currency exchange rate.</li> </ul>
Recurring profits	16,856	15,572	-1,284	
Extraordinary balance	4,992	10	-4,982	•[Previous year] License revenue.
Net profits	13,681	9,574	-4,107	

\* "Others" includes consolidated adjustment. 5

**Care of People Around the World with Patch** 

### Aisamitsu

## 2. Consolidated PL (3) - Summary of the consolidated revised forecast -



Unit:¥ million

### Alsamitsu

# 3. Non-consolidated PL - Performance comparison with the previous period -

				Unit:¥ milli
	Actual performance for FY02/14 (Q1-Q2)	Actual performance for FY02/15 (Q1-Q2)	Change	Percentage change
Net sales	64,293	61,113	-3,180	-4.9%
Rx Business	49,696	46,192	-3,504	-7.1%
OTC Business	10,889	11,534	+645	+5.9%
Intl Business	3,708	3,386	-322	-8.7%
CoGS	21,484	20,013	-1,471	-6.8%
as a % of sales	33.4%	32.7%	_	_
SG&A costs	27,214	27,215	+1	+0.0%
Sales promotion costs	5,727	5,654	-73	-1.3%
Advertising costs	5,234	5,044	-190	-3.6%
R&D spending	4,679	5,021	+342	+7.3%
Others	11,574	11,496	-78	-0.7%
Operating profits	15,594	13,885	-1,709	-11.0%
Recurring profits	16,298	14,533	-1,765	-10.8%
Net profits	13,620	9,345	-4,275	-31.4%

**Care of People Around the World with Patch** 

## Alsamitsu

## 4. Noven $PL\,$ - Performance comparison with the previous period -

			Unit:¥	f million ∉			Unit:\$ t	nousand
	Actual performance for FY02/14 (Q1-Q2)	Actual performance for FY02/15 (Q1-Q2)	Change	Percentage change	Actual performance for FY02/14 (Q1-Q2)	Actual performance for FY02/15 (Q1-Q2)	Change	Percentage change
Net sales *	8,388	10,160	+1,772	+21.1%	87,475	99,384	+11,909	+13.6%
Noven Women's Health	3,808	5,893	+2,085	+54.8%	39,723	57,663	+17,940	+45.2%
Noven Others	4,580	4,267	-313	-6.8%	47,752	41,721	-6,031	-12.6%
CoGS	4,548	5,592	+1,044	+23.0%	47,427	54,702	+7,275	+15.3%
as a % of sales	54.2%	55.0%	-	-	54.2%	55.0%	-	-
SG&A costs	7,290	8,677	+1,387	+19.0%	76,026	84,883	+8,857	+11.6%
Sales promotion costs	914	2,723	+1,809	+197.9%	9,540	26,641	+17,101	+179.3%
Advertising costs	1,068	30	-1,038	-97.2%	11,140	301	-10,839	-97.3%
R&D spending	1,899	1,715	-184	-9.7%	19,805	16,785	-3,020	-15.2%
Others	3,409	4,207	+798	+23.4%	35,540	41,156	+5,616	+15.8%
Operating profits	-3,450	-4,109	-659	-	-35,978	-40,201	-4,223	-
Nonoperating balance	3,996	4,912	+916	+22.9%	41,672	48,056	+6,384	+15.3%
Equity in earnings of Novogyne	5,555	5,860	+305	+5.5%	57,934	57,330	-604	-1.0%
Amortization of fair value adjustment to investment in Novogyne	-1,712	-945	+767	_	-17,855	-9,250	+8,605	_
Recurring profits	546	803	+257	+47.1%	5,693	7,854	+2,161	+38.0%
Net profits	475	499	+24	+5.1%	4,962	4,884	-78	-1.6%
Exchange rate (¥/USD)	¥95.90	¥102.23						

8

# 5. Sales results by product (1) Rx Business / CPUISamics Performance comparison with the previous period

Unit:¥ million

disamitsu

		ual performa Y02/14 (Q1		Actual performance for FY02/15 (Q1–Q2)		
	Total	Japan	Overseas	Total	Japan	Overseas
Rx Business	58,360	49,693	8,667	56,354	46,189	10,165
New products	3,359	3,359	_	3,655	3,655	-
Fentos <sub>®</sub> Tape	1,757	1,757	_	1,973	1,973	_
Norspan <sub>®</sub> Tape	903	903	_	1,039	1,039	-
Neoxy <sub>®</sub> Tape	493	493	_	367	367	_
Other new products	206	206	-	276	276	-
Mohrus®products+Others	46,733	46,334	399	42,673	42,534	139
Mohrus <sub>®</sub> Tape	38,939	38,853	86	35,665	35,614	51
Mohrus <sub>®</sub> Pap	3,679	3,679	-	3,274	3,274	-
Others	4,115	3,802	313	3,734	3,646	88
Noven Women's Health	3,808	_	3,808	5,893	-	5,893
Minivelle®	783	-	783	3,436	-	3,436
Vivelle-Dot <sup>®</sup> products	2,547	-	2,547	1,795	-	1,795
CombiPatch <sup>®</sup> products	478	-	478	365	-	365
Brisdelle <sup>®</sup>	_	-	-	297	-	297
Noven Others	4,460	-	4,460	4,133	_	4,133
Daytrana®	3,240	-	3,240	3,478	-	3,478
Other Noven products	1,220	-	1,220	655	-	655

9

Care of People Around the World with Patch


### Alsamitsu

# 5. Sales results by product (2) Rx Business / Performance comparison with the previous period

Unit:¥ million

		Actual performance for FY02/14 (Q1–Q2)			Actual performance for FY02/15 (Q1-Q2)			
	Total	Japan	Overseas	Total	Japan	Overseas		
OTC Business	17,415	10,886	6,529	19,129	11,531	7,598		
Salonpas <sub>®</sub> products	8,312	3,473	4,839	9,685	3,730	5,955		
Salonsip <sub>®</sub> products	2,389	1,615	774	2,567	1,728	839		
$Air_{\scriptscriptstyle{\mathbb{R}}} Salonpas_{\scriptscriptstyle{\mathbb{R}}} products$	1,277	923	354	1,235	843	392		
Feitas <sub>®</sub> products	1,602	1,602	_	2,247	2,247	_		
Butenalock <sub>®</sub> products	1,407	1,407	-	1,557	1,557	-		
Allegra <sup>®</sup> FX	1,186	1,186	-	774	774	_		
Others	1,242	680	562	1,064	652	412		


# 6. Trends of second-generation non-steroidal anti-inflammatory patch in Japan (1)



disamitsu

disamitsu

# 6. Trends of second-generation non-steroidal anti-inflammatory patch in Japan (2)



## 7. R&D Pipeline

	Stage	Theme	Target	Dosage Form	Characteristics	Next Step
1	Filed (ANDA)	HP-1010	USA	Adhesive skin patch	Relief of pain associated with post-herpetic neuralgia	To be approved in FY15
2	Filed (ANDA)	HP-1030	USA	Adhesive skin patch	Alzheimer's disease	No disclosure
3	Phase3 being prepared	ATS	USA	Adhesive skin patch	Attention Deficit Hyperactivity Disorder (ADHD)	Phase3 in FY14
4	Phase3 being prepared	HP-3000	JPN	Adhesive skin patch	Parkinson's disease	Phase3 in FY14
5	Phase3 being prepared	HP-3060	JPN	Adhesive skin patch	Allergic rhinitis	Phase3 in FY15
6	Phase2	HP-3000	JPN	Adhesive skin patch	Idiopathic restless legs syndrome	Phase3 in FY15
7	Phase1	HP-3070	USA	Adhesive skin patch	Schizophrenia	Phase2 in FY15

13

Care of People Around the World with Patch

Aisamitsu

disamitsu

# Improving Quality of Life Around the World



Q2 FY02/2015 Results Oct. 9th, 2014 Hisamitsu Pharmaceutical Co., Inc.

**Care of People Around the World with Patch** 

# **Additional data**

15

disamitsu

Care of People Around the World with Patch

## **Forecast of Consolidated PL**

			Unit:¥ million
	Earnings forecast for FY02/15 (Q1-Q4) <sup>*1</sup>	Actual performance for FY02/15 (Q1-Q2)	Percentage
Net sales	161,900	77,052	47.6%
CoGS	59,500	27,903	46.9%
as a % of sales	36.8%	36.2%	
SG&A costs <sup>*2</sup>	82,000	38,795	47.3%
Sales promotion costs	18,700	9,248	49.5%
Advertising costs	13,000	5,800	44.6%
R&D spending	14,000	6,732	48.1%
Others	36,300	17,015	46.9%
Operating profits	20,400	10,355	50.8%
Recurring profits	27,800	15,572	56.0%
Net profits	18,000	9,574	53.2%

\*1 Disclose of earnings forecast for FY02/15 as of Apr 10, 2014.
\*2 Detail of "Sales promotion costs" & "Others" for SG&A costs have been changed for FY02/15 as of Jul 10, 2014.
16

**Care of People Around the World with Patch** 

### disamitsu

## **Forecast of Non-consolidated PL**

			Unit:¥ million
	Earnings forecast for FY02/15 (Q1-Q4) <sup>*</sup>	Actual performance for FY02/15 (Q1-Q2)	Percentage
Net sales	127,300	61,113	48.0%
Rx Business	97,700	46,192	47.3%
OTC Business	21,200	11,534	54.4%
Intl Business	8,400	3,386	40.3%
CoGS	44,000	20,013	45.5%
as a % of sales	34.6%	32.7%	
SG&A costs	56,200	27,215	48.4%
Sales promotion costs	12,500	5,654	45.2%
Advertising costs	8,400	5,044	60.0%
R&D spending	10,300	5,021	48.7%
Others	25,000	11,496	46.0%
Operating profits	27,100	13,885	51.2%
Recurring profits	27,800	14,533	52.3%
Net profits	18,200	9,345	51.3%

\* Change of earnings forecast for FY02/15 as of Oct 9, 2014.

Care of People Around the World with Patch

## **Forecast of Noven PL**

		Unit	:¥ million		Unit:S	5 thousand
	Earnings forecast for FY02/15 (Q1-Q2) <sup>*1</sup>	Actual performance for FY02/15 (Q1-Q2)	Percentage	Earnings forecast for FY02/15 (Q1-Q2) <sup>*1</sup>	Actual performance for FY02/15 (Q1-Q2)	Percentage
Net sales <sup>*2</sup>	22,900	10,160	44.4%	229,000	99,384	43.4%
Noven Women's Health	15,300	5,893	38.5%	153,000	57,663	37.7%
Noven Others	7,600	4,267	56.1%	76,000	41,721	54.9%
CoGS	11,200	5,592	49.9%	112,000	54,702	48.8%
as a % of sales	48.9%	55.0%	-	48.9%	55.0%	-
SG&A costs	19,400	8,677	44.7%	194,000	84,883	43.8%
Sales promotion costs	4,800	2,723	56.7%	48,000	26,641	55.5%
Advertising costs	3,000	30	1.0%	30,000	301	1.0%
R&D spending	3,700	1,715	46.4%	37,000	16,785	45.4%
Others	7,900	4,207	53.3%	79,000	41,156	52.1%
Operating profits	-7,700	-4,109	_	-77,000	-40,201	-
Nonoperating balance	6,700	4,912	73.3%	67,000	48,056	71.7%
Equity in earnings of Novogyne	7,000	5,860	83.7%	70,000	57,330	81.9%
Amortization of fair value adjustment to investment in Novogyne	-1,100	-945	-	-11,000	-9,250	-
Recurring profits	-1,000	803	-	-10,000	7,854	-
Net profits	-600	499	_	-6,000	4,884	-
Exchange rate (¥/USD)	¥100.00	¥102.23				

\* 1 Change of earnings forecast for FY02/15 as of Oct 9, 2014.\* 2 Results before consolidated adjustment.

## Alsamitsu

17

### disamitsu

## Forecast of Sales by product - Rx Business -

					U	nit:¥ millio
		nings foreca (02/15(Q1-		Actual performance for FY02/15 (Q1–Q2)		
	Total	Japan	Overseas	Total	Japan	Overseas
Rx Business	121,550	97,700	23,850	56,354	46,189	10,165
New products	11,100	11,100	-	3,655	3,655	-
Fentos <sub>®</sub> Tape	4,700	4,700	-	1,973	1,973	-
Norspan <sub>®</sub> Tape	4,000	4,000	-	1,039	1,039	-
Neoxy <sub>®</sub> Tape	1,550	1,550	_	367	367	_
Other new products	850	850	_	276	276	_
Mohrus <sub>®</sub> products+Others	87,550	86,600	950	42,673	42,534	139
Mohrus <sub>®</sub> Tape	74,050	73,800	250	35,665	35,614	51
Mohrus <sub>®</sub> Pap	6,100	6,100	_	3,274	3,274	_
Others	7,400	6,700	700	3,734	3,646	88
Noven Women's Health	15,300	-	15,300	5,893	-	5,893
Minivelle®	8,400	-	8,400	3,436	-	3,436
Vivelle-Dot <sup>®</sup> products	3,600	-	3,600	1,795	-	1,795
CombiPatch <sup>®</sup> products	2,000	-	2,000	365	-	365
Brisdelle®	1,300	-	1,300	297		297
Noven Others	7,600	-	7,600	4,133	-	4,133
Daytrana®	6,300	_	6,300	3,478	-	3,478
Other Noven products	1,300	_	1,300	655	-	655
		* Chan	ge of earnings	forecast for FY0	$\frac{02}{15}$ as of Oct	9, 2014.

19

Care of People Around the World with Patch

### Alsamitsu

## Forecast of Sales by product - OTC Business -

					U	nit:¥ millio	
		Earnings forecast for FY02/15(Q1-Q4) <sup>*</sup>			Actual performance for FY02/15 (Q1-Q2)		
	Total	Japan	Overseas	Total	Japan	Overseas	
OTC Business	37,400	21,200	16,200	19,129	11,531	7,598	
Salonpas <sub>®</sub> products	19,750	7,300	12,450	9,685	3,730	5,955	
Salonsip <sub>®</sub> products	4,950	3,200	1,750	2,567	1,728	839	
$Air_{\scriptscriptstyle{ extsf{B}}}$ Salonpas $_{\scriptscriptstyle{ extsf{B}}}$ products	2,100	1,250	850	1,235	843	392	
Feitas <sub>®</sub> products	4,100	4,100	-	2,247	2,247	_	
Butenalock <sub>®</sub> products	1,850	1,850	-	1,557	1,557	_	
Allegra <sup>®</sup> FX	2,000	2,000	-	774	774	_	
Others	2,650	1,500	1,150	1,064	652	412	

20